Full-Time

Cross GBU Performance Lead

Deadline 7/26/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

No salary listed

Sant Cugat del Vallès, Barcelona, Spain

Hybrid

60% home office / week

Category
🚚Operations & Logistics (1)
Required Skills
Power BI
Supply Chain Management
SAP Products
Data Analysis
Requirements
  • Significant experience in supply chain management, ideally within the biopharma industry.
  • Proven record of implementing strategic initiatives and driving performance improvements at a global level.
  • Strong leadership, communication, and interpersonal skills.
  • Ability to collaborate and influence stakeholders across different functions and geographies.
  • High emotional intelligence and strong problem-solving skills.
  • Experience in training and capacity to transfer knowledge with pedagogy.
  • Adept at developing and managing key performance indicators (KPIs) for critical metrics.
  • Proficient in preparing materials for strategic meetings.
  • Strong analytical skills and proficient in utilizing various tools and methodologies for data analysis and process improvement.
  • Knowledge of Kinaxis and Power BI is a must; Sceye & SAP experience is a plus.
  • Degree in Supply Chain Management, Business Administration, Engineering, or a related field.
  • Additional certifications such as APICS are highly advantageous.
  • Fluency in English is essential; proficiency in additional languages is a valuable asset.
Responsibilities
  • Establish and monitor key performance indicators (KPIs) in the monthly cycle for inventories, cycle time, adherence, and other critical metrics across all business units.
  • Support in the preparation of comprehensive materials for cross-GBU IBP meetings.
  • Support and coordinate supply planning activities across the three business units and the External Manufacturing team.
  • Conduct detailed data analysis to identify trends, issues, and opportunities for improvement in supply planning processes.
  • Develop and distribute regular reports on supply planning performance, including insights and recommendations for continuous improvement.
  • Collaborate with the Center of Excellence to propose system enhancements and participate in testing.
  • Prepare and run the community of users meetings to push for standardization and tool adoption.
  • Identify and implement performance improvement initiatives to enhance supply chain operations.
  • Facilitate collaboration and communication among supply planning teams, managers, and other stakeholders.
  • Provide training and support to supply planning teams to enhance their skills and knowledge.
  • Lead and manage projects related to supply planning and system enhancements.
  • Share and implement best practices across business units to standardize and optimize supply planning processes and tools.
Desired Qualifications
  • Additional certifications such as APICS are highly advantageous.
  • Proficiency in additional languages is a valuable asset.

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions in immunology, oncology, and rare diseases, as well as to produce vaccines. Sanofi's products include prescription medicines and over-the-counter items, which are made available to patients, healthcare professionals, and governments. The company operates by investing in scientific research and forming partnerships to enhance its product offerings. It generates revenue from the sale of its pharmaceutical products and vaccines, along with collaborations with other healthcare organizations. What sets Sanofi apart from its competitors is its strong emphasis on R&D and its ability to navigate complex regulatory environments globally. The company aims to improve health outcomes and the quality of life for individuals by providing effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its portfolio in rare immunological diseases.
  • The approval of Dupixent for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's investment in Adagene supports innovative cancer treatment development.

What critics are saying

  • Large-scale acquisitions may strain Sanofi's financial stability if returns are insufficient.
  • Regulatory challenges could delay the market entry of new treatments like tolebrutinib.
  • Dependence on strategic partnerships may pose risks if collaborations don't meet expectations.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts focus on unmet medical needs in immunology and oncology.
  • The company leverages strategic partnerships to enhance its product pipeline and market reach.
  • Sanofi's global presence allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...